Comunicati Stampa
Salute e Benessere

Asia Book of Records Honors Cipla (Emerging Markets & Europe business unit) for Record-Breaking Doctor engagement on COPD Awareness Initiative

This achievement has been recognised by the Asia Book of Records for engaging the largest number of doctors in a COPD awareness campaign during COPD Awareness Month. This achievement has been recognised by the Asia Book of Records for engaging the largest number of doctors in a COPD awareness campaign during COPD Awareness Month. Commenting on this recognition,Swapn Malpani, CEO – Cipla EMEUsaid, "COPD is recognized as a progressive lung condition and ranks as the fourth leading cause of...
MUMBAI, India, (informazione.news - comunicati stampa - salute e benessere)

This achievement has been recognised by the Asia Book of Records for engaging the largest number of doctors in a COPD awareness campaign during COPD Awareness Month.

Commenting on this recognition, said, "COPD is recognized as a progressive lung condition and ranks as the fourth leading cause of death worldwide. In 2021, it accounted for about 3.5 million deaths, which is roughly 5% of all deaths globally. By encouraging doctors to participate in the 'Take Charge – I Pledge' campaign, our aim was to highlight the significance of timely diagnosis and effective management in enhancing long-term health outcomes. The campaign aimed to strengthen the doctor-patient relationship by promoting open dialogue, which can result in better understanding and improved care for those living with COPD."

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India , South Africa , North America , and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3 largest in pharma in India (IQVIA MAT Dec'24), Largest in the pharma prescription market in South Africa (IQVIA MAT Nov'24), and 4 largest by prescription in the US Gx (Repulses + MDI) products (IQVIA MAT Nov'24). For more, please visit www.cipla.com, or click on Twitter, Facebook, LinkedIn.


Investor Relations   
E-mail: Investor.Relations@cipla.com      

Logo: https://mma.prnewswire.com/media/947146/1865863/Cipla_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/asia-book-of-records-honors-cipla-emerging-markets--europe-business-unit-for-record-breaking-doctor-engagement-on-copd-awareness-initiative-302363172.html

Ufficio Stampa
 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
Allegati
Non disponibili